Follow Binaytara on FacebookFollow Binaytara on XFollow Binaytara on LinkedinFollow Binaytara on BlueskyFollow Binaytara on Instagram
Binaytara logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
Wednesday, August 19, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Equity
About Us
  • Contributors
  • Ethics and Disclosure Policy
  • Editorial Standards & Corrections Policy
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment

Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment

August 11, 2026

CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It

CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It

August 11, 2026

Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise

Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise

August 7, 2026

Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance

Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance

August 7, 2026

Alcohol and Cancer: How Much Risk Does Drinking Add?

Alcohol and Cancer: How Much Risk Does Drinking Add?

August 6, 2026

CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia

CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia

Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care

Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care

Share Article

Get the Quick Bites delivered to your inbox daily

Binaytara logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved

Follow Binaytara on FacebookFollow Binaytara on BlueskyFollow Binaytara on LinkedinFollow Binaytara on YoutubeFollow Binaytara on TwitterFollow Binaytara on Instagram